Published in Cancer Cell on May 01, 2004
Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol (2008) 6.90
Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol (2007) 2.70
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer (2013) 2.41
The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res (2008) 2.17
Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol (2007) 2.07
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res (2010) 2.01
Multi-targeted prevention of cancer by sulforaphane. Cancer Lett (2008) 1.98
Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. Am J Physiol Lung Cell Mol Physiol (2009) 1.82
HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell (2008) 1.67
HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol (2012) 1.67
Cytoskeleton out of the cupboard: colon cancer and cytoskeletal changes induced by loss of APC. Nat Rev Cancer (2006) 1.53
Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci U S A (2009) 1.46
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol (2008) 1.42
Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays. PLoS One (2015) 1.40
Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics (2006) 1.39
Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. Neuro Oncol (2008) 1.39
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics (2013) 1.38
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis (2013) 1.37
Histone deacetylase 2 is required for chromatin condensation and subsequent enucleation of cultured mouse fetal erythroblasts. Haematologica (2010) 1.25
HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure. PLoS One (2013) 1.21
The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget (2010) 1.20
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat (2011) 1.18
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology (2008) 1.18
Identification and analysis of tumour-associated antigens in hepatocellular carcinoma. Br J Cancer (2005) 1.16
HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling. Cancer Biol Ther (2008) 1.13
Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS One (2011) 1.12
Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly. Mol Cancer (2011) 1.11
A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res (2009) 1.07
Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors. J Biol Chem (2009) 1.07
HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Oncogene (2009) 1.06
Chromatin-modifying enzymes as therapeutic targets--Part 1. Expert Opin Ther Targets (2008) 1.04
Vitamin D and the epigenome. Front Physiol (2014) 1.04
Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res (2008) 1.04
Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase. EMBO Mol Med (2014) 1.03
Histone deacetylases 9 and 10 are required for homologous recombination. J Biol Chem (2011) 1.03
Histone deacetylase inhibitors and cell death. Cell Mol Life Sci (2014) 1.00
Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res (2010) 0.99
Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol (2008) 0.99
The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother Pharmacol (2010) 0.99
Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res (2009) 0.99
Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics (2010) 0.99
Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int J Colorectal Dis (2008) 0.97
Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One (2012) 0.97
Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis. PLoS One (2011) 0.97
A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin. Oncotarget (2014) 0.96
Long non-coding RNAs and their implications in cancer epigenetics. Biosci Rep (2013) 0.95
Cancer epigenetics: above and beyond. Toxicol Mech Methods (2011) 0.95
3,3'-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin. Cancer Prev Res (Phila) (2009) 0.95
Apc(MIN) modulation of vitamin D secosteroid growth control. Carcinogenesis (2010) 0.94
Epigenetic changes in colorectal cancer. Chin J Cancer (2011) 0.94
Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors. Curr Top Med Chem (2009) 0.93
The Wnt-dependent signaling pathways as target in oncology drug discovery. Invest New Drugs (2006) 0.93
Beef meat promotion of dimethylhydrazine-induced colorectal carcinogenesis biomarkers is suppressed by dietary calcium. Br J Nutr (2007) 0.93
HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Med J (2016) 0.93
The regulatory role of c-MYC on HDAC2 and PcG expression in human multipotent stem cells. J Cell Mol Med (2011) 0.93
Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration. Pharmaceuticals (Basel) (2011) 0.89
The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. J Hematol Oncol (2015) 0.89
HDAC2 promotes eIF4E sumoylation and activates mRNA translation gene specifically. J Biol Chem (2010) 0.88
A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res (2010) 0.87
Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. J Biomed Biotechnol (2010) 0.87
Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas. Korean J Pathol (2012) 0.87
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Oncotarget (2014) 0.87
Histone Deacetylase Inhibitors Activate Tristetraprolin Expression through Induction of Early Growth Response Protein 1 (EGR1) in Colorectal Cancer Cells. Biomolecules (2015) 0.86
Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog. Genes Cancer (2015) 0.86
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett (2012) 0.86
Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem (2013) 0.86
Recent advances in histone deacetylase targeted cancer therapy. Surg Today (2010) 0.85
Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells. PLoS One (2013) 0.85
Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells. PLoS One (2015) 0.84
HDAC2 and TXNL1 distinguish aneuploid from diploid colorectal cancers. Cell Mol Life Sci (2011) 0.84
A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells. Invest New Drugs (2011) 0.84
Cubilin expression is monoallelic and epigenetically augmented via PPARs. BMC Genomics (2013) 0.84
Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi). PLoS One (2013) 0.83
Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Mol Cancer (2008) 0.83
Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo. PLoS One (2012) 0.82
Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer. Am J Cancer Res (2015) 0.82
Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2. Cancer Res (2014) 0.82
Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis. Oncotarget (2015) 0.82
Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer. Clin Cancer Res (2010) 0.82
Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncol (2011) 0.81
Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells. Int J Clin Oncol (2011) 0.81
USP4 inhibits p53 and NF-κB through deubiquitinating and stabilizing HDAC2. Oncogene (2015) 0.81
15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells. Oncogene (2009) 0.80
Polyphenols from green tea inhibit the growth of melanoma cells through inhibition of class I histone deacetylases and induction of DNA damage. Genes Cancer (2015) 0.79
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer. Oncotarget (2016) 0.79
SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. Cancer Biol Ther (2014) 0.79
Acetyltransferase p300/CBP associated Factor (PCAF) regulates crosstalk-dependent acetylation of histone H3 by distal site recognition. ACS Chem Biol (2014) 0.79
Monitoring the effect of belinostat in solid tumors by H4 acetylation. APMIS (2008) 0.79
Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects. Onco Targets Ther (2012) 0.79
Differential mRNA expression levels of human histone-modifying enzymes in normal karyotype B cell pediatric acute lymphoblastic leukemia. Int J Mol Sci (2013) 0.79
Further characterization of HDAC and SIRT gene expression patterns in pancreatic cancer and their relation to disease outcome. PLoS One (2014) 0.79
Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise? Front Oncol (2014) 0.78
HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape. Oncotarget (2015) 0.78
The Impact of External Factors on the Epigenome: In Utero and over Lifetime. Biomed Res Int (2016) 0.77
Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis. J Korean Med Sci (2015) 0.77
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis. J Pharmacol Exp Ther (2013) 0.77
Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci (2017) 0.77
Making sense of HDAC2 mutations in colon cancer. Gastroenterology (2008) 0.76
Epigenetic mechanisms underlying diet-sourced compounds in the prevention and treatment of gastrointestinal cancer. Anticancer Agents Med Chem (2012) 0.76
Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis (2004) 6.83
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J (2003) 2.81
Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc Natl Acad Sci U S A (2009) 2.34
Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res (2007) 2.26
Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J Clin Microbiol (2006) 1.96
Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res (2007) 1.54
Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann Surg (2013) 1.53
Colorectal cancer surgery remains effective with rising patient age. Int J Colorectal Dis (2014) 1.49
Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol (2008) 1.46
A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters. Genes Dev (2004) 1.46
Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival. Int J Colorectal Dis (2010) 1.31
The specific role of histone deacetylase 2 in adult neurogenesis. Neuron Glia Biol (2010) 1.27
Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer. Ann Surg (2012) 1.25
Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg (2013) 1.23
Prediction of prognosis is not improved by the seventh and latest edition of the TNM classification for colorectal cancer in a single-center collective. Ann Surg (2011) 1.19
Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol (2008) 1.16
Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol (2005) 1.13
Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer (2007) 1.13
The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle (2007) 1.11
Expression of the mitotic checkpoint gene MAD2L2 has prognostic significance in colon cancer. Int J Cancer (2007) 1.09
IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol (2006) 1.01
TCDD induces c-jun expression via a novel Ah (dioxin) receptor-mediated p38-MAPK-dependent pathway. Oncogene (2005) 1.00
Electrophoretic analysis of the mitochondrial outer membrane rupture induced by permeability transition. Anal Chem (2008) 0.99
Gene expression profiles of different clinical stages of colorectal carcinoma: toward a molecular genetic understanding of tumor progression. Int J Colorectal Dis (2005) 0.98
Clinical use of the hyperthermia treatment planning system HyperPlan to predict effectiveness and toxicity. Int J Radiat Oncol Biol Phys (2003) 0.96
The candidate tumor suppressor SASH1 interacts with the actin cytoskeleton and stimulates cell-matrix adhesion. Int J Biochem Cell Biol (2011) 0.95
Microarray-based response prediction in esophageal adenocarcinoma. Clin Cancer Res (2009) 0.95
Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther (2008) 0.95
In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials (2013) 0.95
Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis. Cell Cycle (2004) 0.95
Differential immunization identifies PHB1/PHB2 as blood-borne tumor antigens. Oncogene (2004) 0.95
IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis. Int J Cancer (2009) 0.95
Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Ann Surg Oncol (2010) 0.94
Langendorff heart: a model system to study cardiovascular effects of engineered nanoparticles. ACS Nano (2011) 0.91
UVA inactivates protein tyrosine phosphatases by calpain-mediated degradation. EMBO Rep (2004) 0.90
Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo. Mol Cancer Res (2009) 0.89
Structure of the N-terminal domain of the adenylyl cyclase-associated protein (CAP) from Dictyostelium discoideum. Structure (2003) 0.89
Cutting edge: Divergent cell-specific functions of MyD88 for inflammatory responses and organ injury in septic peritonitis. J Immunol (2012) 0.89
Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. Expert Rev Vaccines (2014) 0.88
Tenascin-C downregulates wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model. Cell Rep (2013) 0.87
Tumor endothelial marker 5 expression in endothelial cells during capillary morphogenesis is induced by the small GTPase Rac and mediates contact inhibition of cell proliferation. Exp Cell Res (2009) 0.87
APC inactivation associates with abnormal mitosis completion and concomitant BUB1B/MAD2L1 up-regulation. Gastroenterology (2007) 0.87
Epithelial morphogenesis and intestinal cancer: new insights in signaling mechanisms. Adv Cancer Res (2008) 0.87
PKCalpha tumor suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1. Exp Cell Res (2009) 0.86
Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice. Hepatology (2014) 0.86
Differential impact of diesel particle composition on pro-allergic dendritic cell function. Toxicol Sci (2009) 0.86
Immunoinhibitory adapter protein Src homology domain 3 lymphocyte protein 2 (SLy2) regulates actin dynamics and B cell spreading. J Biol Chem (2011) 0.85
Gradient index ductoscopy and intraductal biopsy of intraductal breast lesions. Am J Surg (2007) 0.85
Flavonoids alter P-gp expression in intestinal epithelial cells in vitro and in vivo. Mol Nutr Food Res (2007) 0.84
Discovery of a novel tumour metastasis-promoting gene, NVM-1. J Pathol (2011) 0.84
Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI. Anal Bioanal Chem (2014) 0.84
Clinical evaluation of a fully automated CMV PCR assay. J Clin Virol (2011) 0.83
Prediction of metastasis and recurrence in colorectal cancer based on gene expression analysis: ready for the clinic? Cancers (Basel) (2011) 0.83
The human submandibular gland: immunohistochemical analysis of SNAREs and cytoskeletal proteins. J Histochem Cytochem (2011) 0.82
Endogenous expression of the sodium iodide symporter mediates uptake of iodide in murine models of colorectal carcinoma. Int J Cancer (2009) 0.82
Isolation of highly pure rat liver mitochondria with the aid of zone-electrophoresis in a free flow device (ZE-FFE). Methods Mol Biol (2008) 0.82
Deficiency of caveolin-1 in Apc(min/+) mice promotes colorectal tumorigenesis. Carcinogenesis (2013) 0.82
Thrombin-induced shedding of tumour endothelial marker 5 and exposure of its RGD motif are regulated by cell-surface protein disulfide-isomerase. Biochem J (2012) 0.80
Tumor-specific targeting of pancreatic cancer with Shiga toxin B-subunit. Mol Cancer Ther (2011) 0.78
Detection of circulating tumor-associated antigen depends on the domains recognized by the monoclonal antibodies used: N-terminal trimmed EpCAM-levels are much higher than untrimmed forms. Immunol Lett (2012) 0.77
Genes upregulated in a metastasizing human colon carcinoma cell line. Int J Cancer (2005) 0.75
Spatial organization of the tenascin-C microenvironment in experimental and human cancer. Cell Adh Migr (2015) 0.75
Heterogeneous metastasis efficiency of isogenic orthotopic colon cancer xenografts reveals distinctive gene expression profiles. Tumour Biol (2007) 0.75